ITGA3 and ITGB4 expression biomarkers estimate the risks of locoregional and hematogenous dissemination of oral squamous cell carcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Nagata, Masaki ^a   Noman, Arhab A ^a   Suzuki, Kenji ^a   Kurita, Hiroshi ^b   Ohnishi, Makoto ^c   Ohyama, Tokio ^c   Kitamura, Nobutaka ^d   Kobayashi, Takanori ^a   Uematsu, Kohya ^a   Takahashi, Katsu ^e   Kodama, Naoki ^a   Kawase, Tomoyuki ^a   Hoshina, Hideyuki ^a   Ikeda, Nobuyuki ^a   Shingaki, Susumu ^a   Takagi, Ritsuo ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGAOKA RED CROSS HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Integrin alpha3; Integrin beta4; Metastasis; Squamous cell carcinoma

Indexed keywords

ALPHA3 INTEGRIN; ANTINEOPLASTIC AGENT; BETA4 INTEGRIN; CD9 ANTIGEN; PLAKOGLOBIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CD9 GENE; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTEGRIN ALPHA3 GENE; INTEGRIN BETA4 GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; PLAKOGLOBIN GENE; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT FAILURE; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD9; CARCINOMA, SQUAMOUS CELL; DESMOPLAKINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INTEGRIN ALPHA3; INTEGRIN BETA4; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84883611645     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-410     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
2. Yako-Suketomo H, Matsuda T. Comparison of time trends in lip, oral cavity and pharynx cancer mortality (1990-2006) between countries based on the WHO mortality database. Jpn J Clin Oncol 2010, 40:1118-1119. 10.1093/jjco/hyq202, 20978186.
3. Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z, Vourvachis M, Karavidas K, Jay A, Sandison A, Thomas GJ, Kalavrezos N, Hopper C. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol 2010, 2:9. 10.1186/1758-3284-2-9, 2882907, 20406474.
4. Sessions DG, Lenox J, Spector GJ, Chao C, Chaudry OA. Analysis of treatment results for base of tongue cancer. Laryngoscope 2003, 113:1252-1261. 10.1097/00005537-200307000-00026, 12838028.
5. Slootweg PJ, Hordijk GJ, Schade Y, van Es RJ, Koole R. Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncol 2002, 38:500-503. 10.1016/S1368-8375(01)00092-6, 12110346.
6. Weijers M, Snow GB, Bezemer DP, van der Wal JE, van der Waal I. The status of the deep surgical margins in tongue and floor of mouth squamous cell carcinoma and risk of local recurrence; an analysis of 68 patients. Int J Oral Maxillofac Surg 2004, 33:146-149. 10.1054/ijom.2002.0469, 15050070.
7. Ganly I, Patel S, Shah J. Early stage squamous cell cancer of the oral tongue-clinicopathologic features affecting outcome. Cancer 2012, 118:101-111. 10.1002/cncr.26229, 21717431.
8. León X, Quer M, Orús C, del Prado Venegas M, López M. Distant metastases in head and neck cancer patients who achieved locoregional control. Head Neck 2000, 22:680-686. 10.1002/1097-0347(200010)22:7<680::AID-HED7>3.0.CO;2-J, 11002323.
9. Infante-Cossio P, Torres-Carranza E, Cayuela A, Hens-Aumente E, Pastor-Gaitan P, Gutierrez-Perez JL. Impact of treatment on quality of life for oral and oropharyngeal carcinoma. Int J Oral Maxillofac Surg 2009, 38:1052-1058. 10.1016/j.ijom.2009.06.008, 19596557.
10. Yamamoto E, Kohama G, Sunakawa H, Iwai M, Hiratsuka H. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 1983, 51:2175-2180. 10.1002/1097-0142(19830615)51:12<2175::AID-CNCR2820511205>3.0.CO;2-M, 6189571.
11. Rahima B, Shingaki S, Nagata M, Saito C. Prognostic significance of perineural invasion in oral and oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004, 97:423-431. 10.1016/j.tripleo.2003.10.014, 15088027.
12. Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (I). Oral Oncol 2010, 46:630-635. 10.1016/j.oraloncology.2010.06.006, 20637681.
13. Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II). Oral Oncol 2010, 46:636-643. 10.1016/j.oraloncology.2010.06.008, 20637679.
14. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shingaki S, Kaji M, Saku T, Takagi R. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer 2003, 106:683-689. 10.1002/ijc.11283, 12866027.
15. Kurokawa A, Nagata M, Kitamura N, Noman AA, Ohnishi M, Ohyama T, Kobayashi T, Shingaki S, Takagi R. Diagnostic value of integrin alpha3, beta4, and beta5 gene expression levels for the clinical outcome of tongue squamous cell carcinoma. Cancer 2008, 112:1272-1281. 10.1002/cncr.23295, 18224668.
16. Hirano C, Nagata M, Noman AA, Kitamura N, Ohnishi M, Ohyama T, Kobayashi T, Suzuki K, Yoshizawa M, Izumi N, Fujita H, Takagi R. Tetraspanin gene expression levels as potential biomarkers for malignancy of gingival squamous cell carcinoma. Int J Cancer 2009, 124:2911-2916. 10.1002/ijc.24297, 19330835.
17. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000, 275:21785-21788. 10.1074/jbc.R000003200, 10801897.
18. Calderwood DA, Shattil SJ, Ginsberg MH. Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling. J Biol Chem 2000, 275:22607-22610. 10.1074/jbc.R900037199, 10801899.
19. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002, 115:3729-3738. 10.1242/jcs.00071, 12235283.
20. Danen EH, Sonnenberg A. Integrins in regulation of tissue development and function. J Pathol 2003, 200:471-480. 10.1002/path.1416, 12845614.
21. DiPersio CM, Hodivala-Dilke KM, Jaenisch R, Kreidberg JA, Hynes RO. alpha3beta1 Integrin is required for normal development of the epidermal basement membrane. J Cell Biol 1997, 137:729-742. 10.1083/jcb.137.3.729, 2139886, 9151677.
22. Gonzales M, Haan K, Baker SE, Fitchmun M, Todorov I, Weitzman S, Jones JC. A cell signal pathway involving laminin-5, alpha3beta1 integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation. Mol Biol Cell 1999, 10:259-270. 10.1091/mbc.10.2.259, 25167, 9950675.
23. Manohar A, Shome SG, Lamar J, Stirling L, Iyer V, Pumiglia K, DiPersio CM. Alpha 3 beta 1 integrin promotes keratinocyte cell survival through activation of a MEK/ERK signaling pathway. J Cell Sci 2004, 117:4043-4054. 10.1242/jcs.01277, 15280429.
24. Miyamoto S, Maruyama A, Okugawa K, Akazawa K, Baba H, Maehara Y, Mekada E. Loss of motility-related protein 1 (MRP1/CD9) and integrin alpha3 expression in endometrial cancers. Cancer 2001, 92:542-548. 10.1002/1097-0142(20010801)92:3<542::AID-CNCR1353>3.0.CO;2-8, 11505398.
25. Hashida H, Takabayashi A, Tokuhara T, Taki T, Kondo K, Kohno N, Yamaoka Y, Miyake M. Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82. Int J Cancer 2002, 97:518-525. 10.1002/ijc.1625, 11802216.
26. Levy S, Shoham T. Protein-protein interactions in the tetraspanin web. Physiology (Bethesda) 2005, 20:218-224.
27. Lazo PA. Functional implications of tetraspanin proteins in cancer biology. Cancer Sci 2007, 98:1666-1677. 10.1111/j.1349-7006.2007.00584.x, 17727684.
28. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 2006, 25:2367-2378. 10.1038/sj.onc.1209269, 16331263.
29. Huang CL, Ueno M, Liu D, Masuya D, Nakano J, Yokomise H, Nakagawa T, Miyake M. MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2. Oncogene 2006, 25:6480-6488. 10.1038/sj.onc.1209654, 16682943.
30. Nievers MG, Schaapveld RQ, Sonnenberg A. Biology and function of hemidesmosomes. Matrix Biol 1999, 18:5-17. 10.1016/S0945-053X(98)00003-1, 10367727.
31. Kowalczyk AP, Bornslaeger EA, Borgwardt JE, Palka HL, Dhaliwal AS, Corcoran CM, Denning MF, Green KJ. The amino-terminal domain of desmoplakin binds to plakoglobin and clusters desmosomal cadherin-plakoglobin complexes. J Cell Biol 1997, 139:773-784. 10.1083/jcb.139.3.773, 2141713, 9348293.
32. Fausser JL, Schlepp O, Aberdam D, Meneguzzi G, Ruch JV, Lesot H. Localization of antigens associated with adherens junctions, desmosomes, and hemidesmosomes during murine molar morphogenesis. Differentiation 1998, 63:1-11. 10.1046/j.1432-0436.1998.6310001.x, 9615388.
33. Gleason B, Adley B, Rao MS, Diaz LK. Immunohistochemical detection of the beta4 integrin subunit in pancreatic adenocarcinoma. J Histochem Cytochem 2005, 53:799-801. 10.1369/jhc.4B6522.2005, 15928331.
34. Brendle A, Lei H, Brandt A, Johansson R, Enquist K, Henriksson R, Hemminki K, Lenner P, Försti A. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 2008, 29:1394-1399. 10.1093/carcin/bgn126, 18550570.
35. Lu S, Simin K, Khan A, Mercurio AM. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res 2008, 14:1050-1058. 10.1158/1078-0432.CCR-07-4116, 18281537.
36. Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H, Mackall C, Li WJ, Tuan RS, Deyrup AT, Khanna C, Helman L. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene 2009, 28:3401-3411. 10.1038/onc.2009.206, 2753583, 19597468.
37. Dutta U, Shaw LM. A key tyrosine (Y1494) in the beta4 integrin regulates multiple signaling pathways important for tumor development and progression. Cancer Res 2008, 68:8779-8787. 10.1158/0008-5472.CAN-08-2125, 2586898, 18974120.
38. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160. 10.1126/science.1208130, 3415217, 21798893.